Premium
Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol.
Author(s) -
Spahn H,
Kirch W,
Mutschler E,
Ohnhaus EE,
Kitteringham NR,
Logering HJ,
Paar D
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02439.x
Subject(s) - phenprocoumon , atenolol , metoprolol , pharmacology , cmax , pharmacokinetics , chemistry , pharmacodynamics , drug interaction , volume of distribution , medicine , warfarin , blood pressure , atrial fibrillation
Pharmacological interactions in both directions between phenprocoumon and atenolol and metoprolol were investigated using a crossover trial. Co‐administration of phenprocoumon did not significantly affect Cmax, tmax, t1/2,22, AUC for atenolol or metoprolol. Co‐administration of metoprolol, but not atenolol, increased mean plasma phenprocoumon concentrations 4 and 6 h after dosing and was caused by a decrease in the apparent volume of distribution. This increase in plasma phenprocoumon was not associated with an increase in prothrombin time or in the total area under the concentration‐time curve. Although the transient increase of phenprocoumon plasma levels caused by metoprolol may be of little clinical significance after a single dose of phenprocoumon, a more important alteration in phenprocoumon disposition and effect should be considered in individual patients on long‐term therapy.